Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ONCE Spark Therapeutics (ONCE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Spark Therapeutics Stock (NASDAQ:ONCE) 30 days 90 days 365 days Advanced Chart Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Spark Therapeutics alerts:Sign Up Key Stats Today's Range$0.18▼$0.1850-Day Range$110.05▼$113.5752-Week Range$34.53▼$114.20VolumeN/AAverage Volume891,560 shsMarket Capitalization$6.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSpark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.Read More… 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Receive ONCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spark Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ONCE Stock News HeadlinesBitcoin breaks $81,000 for first time on Trump trades; UK government sells £1bn of NatWest shares – business liveNovember 11, 2024 | msn.comDenver police investigate deadly hit-and-run at South Sheridan and Evans AvenueNovember 6, 2024 | yahoo.comBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…November 21, 2024 | Crypto 101 Media (Ad)Amazon Prime vs. Walmart+: Which Offers the Better Discount on Gas?November 5, 2024 | finance.yahoo.comOzempic maker Novo Nordisk is working on a once-monthly weight-loss drugNovember 4, 2024 | msn.comHowie Mandel Sparks Tense Debate With ‘X Factor’ Alum Over Liam Payne’s Death On ‘Piers Morgan Uncensored’October 23, 2024 | msn.comChase Ink Business Cash vs. Capital One Spark Cash Plus: 2 Lucrative Cash Back Cards for Business OwnersOctober 23, 2024 | fool.comRecently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst EnthusiasmOctober 11, 2024 | benzinga.comSee More Headlines ONCE Stock Analysis - Frequently Asked Questions How were Spark Therapeutics' earnings last quarter? Spark Therapeutics Inc (NASDAQ:ONCE) issued its earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.34. The biotechnology company earned $25.19 million during the quarter, compared to the consensus estimate of $29.44 million. Spark Therapeutics had a negative net margin of 358.41% and a negative trailing twelve-month return on equity of 59.10%. When did Spark Therapeutics IPO? Spark Therapeutics (ONCE) raised $88 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers. What other stocks do shareholders of Spark Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Spark Therapeutics investors own include Bristol-Myers Squibb (BMY), NVIDIA (NVDA), Brainstorm Cell Therapeutics (BCLI), Meta Platforms (META), Alibaba Group (BABA), Gilead Sciences (GILD) and Micron Technology (MU). Company Calendar Last Earnings8/07/2018Today11/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ONCE CUSIPN/A CIK1609351 Webwww.sparktx.com Phone888-772-7560FaxN/AEmployees368Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,820,000.00 Net Margins-358.41% Pretax MarginN/A Return on Equity-59.10% Return on Assets-33.13% Debt Debt-to-Equity Ratio0.35 Current Ratio4.67 Quick Ratio4.35 Sales & Book Value Annual Sales$64.72 million Price / Sales0.11 Cash FlowN/A Price / Cash FlowN/A Book Value$13.15 per share Price / Book0.01Miscellaneous Outstanding Shares38,523,000Free FloatN/AMarket Cap$6.94 million OptionableNo Data Beta2.05 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:ONCE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spark Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Spark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.